NCAPG2 promotes prostate cancer malignancy and stemness via STAT3/c-MYC signaling.

ABSTRACT:

Background

Prostate cancer (PCa) is the second leading cause of cancer-related mortality among men worldwide, and its incidence has risen substantially in recent years. Therefore, there is an urgent need to identify novel biomarkers and precise therapeutic targets for managing PCa progression and recurrence.

Methods

We investigated the clinical significance of NCAPG2 in PCa by exploring public datasets and our tissue microarray. Receiver operating characteristic (ROC) curve and survival analyses were performed to evaluate the correlation between NCAPG2 and PCa progression. Cell proliferation, wound healing, transwell, flow cytometry, cell cycle, tumor sphere formation, immunofluorescence (IF), co-immunoprecipitation (co-IP), and chromatin immunoprecipitation (ChIP) assays we

SUBMITTER: Zhang E 

PROVIDER: S-EPMC10763290 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature